Sarcopenia in Chronic Kidney Disease Patients
This study is looking at ways to help people with advanced chronic kidney disease (CKD) who also have sarcopenia (muscle loss and weakness). While a high-protein diet usually helps with sarcopenia, it's not recommended for people with poor kidney function. This study will test two different amino acids, Valine and EEA, to see if they can safely improve muscle mass and strength in people aged 45-75 with severe CKD (eGFR of ≤15 mL/min). We want to see if these treatments are practical and helpful. The main goals are to measure changes in muscle strength (handgrip), muscle mass, and physical performance (walking speed) over 14 weeks.
- Study design
- This is an interventional study with 20 planned participants. It will evaluate the effects of Valine or EEA.
- What's involved
- The study procedures are free of cost and do not require significant time commitment. Measurements will be taken at the start and after 14 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 14 weeks, with measurements taken at baseline and at the end of this period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Sarcopenia in Chronic Kidney Disease (CKD) Patients
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Subrata Debnath, PhD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center at San Antonio
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Skeletal muscle strength (handgrip strength test)Baseline to 14 weeks
Change from baseline handgrip strength test value (kg) measured using a hand dynamometer to the end of each 6-Week intervention
- Muscle massBaseline to 14 weeks
Change from baseline muscle mass using a bioelectrical impedance analysis to the end of each 6-Week intervention
- Physical performance (4-meter Walk Gait Speed Test or 4MWT)Baseline to 14 weeks
Change from baseline 4MWT (measured in second) to the end of each 6-Week intervention
- Incidence of patient-reported symptomsBaseline to 14 weeks
Change from baseline (number of symptoms) to the end of each 6-Week intervention